| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |